antisense

Antisense is an early-stage therapeutic candidate being developed by OncBioMune Mexico for the treatment of cancer. It belongs to the class of antisense oligonucleotides (ASOs), which are synthetic single-stranded nucleic acids designed to bind to specific messenger RNA (mRNA) sequences via Watson-Crick base pairing. This binding typically triggers the degradation of the target mRNA by RNase H or physically blocks translation, thereby preventing the production of proteins that contribute to disease pathology. As of the current pipeline status, OncBioMune Mexico has not disclosed the specific genetic target or the clinical development phase for this program, listing it as a generic antisense asset within its oncology portfolio.